By |

Profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Contact Information

Website: www.ucb.com
Email: Antje.Witte@ucb.com
Main Phone: +32 25599999
Address: 60, Allee de la Recherche
City / Town: Brussels
Country: BEL
Postal Code: 1070

Issuer Information

Exchange: OTO
Employees: 7563
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Contact Information

Website: www.ucb.com
Email: Antje.Witte@ucb.com
Main Phone: +32 25599999
Address: 60, Allee de la Recherche
City / Town: Brussels
Country: BEL
Postal Code: 1070

Issuer Information

Exchange: OTO
Employees: 7563
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 88.67 $ 0. (0.00%)
Last Price 88.67 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close 88.67
Last Trade Volume 0 52 Wk Hi 94.30 52 Wk Low 73.70
Market Cap 16.7 bi Ex-Div Date Div Rate 1.43 Yield 1.6110
Shares 188,121,889.00 EPS (TTM) 5.61 PE Ratio 15.80 Exchange OTCPK
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 44.01
Low Target Price Estimate 44.01
Mean Target Price Estimate 44.01
Standard Deviation 0
Date of Most Recent Estimate 03/15/10
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 4 4 4 4